Criticism of the Kyoto Protocol it really didn’t do much." Rising Tide North America claims: "Emission limits do not include emissions by international aviation and shipping, but are in addition to the industrial gases, chlorofluorocarbons, or CFCs, which are dealt with under the 1987 Montreal Protocol on Substances that Deplete the Ozone Layer. The benchmark 1990 emission levels were accepted by the Conference of the Parties of UNFCCC (decision 2/CP.3)" There has been criticism (especially from the United States) over the exemption of developing countries, such as China and India, from having to reduce their greenhouse gas emissions under the Kyoto Protocol. The Bush Administration
Wiley protocol at separate times throughout the period. The protocol is promoted as differing from conventional hormone replacement therapy in several ways: The protocol also includes a follow-up program to monitor the serum of the bioidentical hormones. Wiley has stated that in her opinion, the most important aspect of the protocol is the specific schedule and levels of the hormone doses rather than their bioidentical nature. A patent was granted for the protocol in 2011 for the specific blend of hormones and dosing method. Concerns have been raised that serum levels may not be an acceptable marker for transdermally administered hormones, that